WO1994006799A1 - Remede contre la thrombopenie - Google Patents
Remede contre la thrombopenie Download PDFInfo
- Publication number
- WO1994006799A1 WO1994006799A1 PCT/JP1993/001346 JP9301346W WO9406799A1 WO 1994006799 A1 WO1994006799 A1 WO 1994006799A1 JP 9301346 W JP9301346 W JP 9301346W WO 9406799 A1 WO9406799 A1 WO 9406799A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- hydrogen
- mmol
- mixture
- added
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/044—Pyrrole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
Definitions
- the present invention relates to a therapeutic agent for thrombocytopenia and a novel indoleforce rubazole derivative.
- the therapeutic agent for thrombocytopenia is expected to reduce thrombocytopenia, a side effect of cancer chemotherapy and bone marrow transplantation, or as a therapeutic agent for various diseases associated with thrombocytopenia.
- hematopoietic factors that promote platelet production are interleukin (IL) 6 and IL11.
- indole-active rubazole derivatives have inhibitory activity, antibacterial activity or antitumor activity against various protein kinases such as protein kinase C [Japanese Patent Application Laid-Open Nos. 62-155284 and 62-220196 -A- 238011), JP-A-63-295588, JP-A-63-295589, JP-A-1-68689 (EP-A-323171), W088-07045 (USP4923986), W089-07105 (EP-A- 383919) ]. Disclosure of the invention
- R 1 represents hydrogen, lower alkyl, lower alkanol, benzyl or amino
- R 2 represents hydrogen, hydroxy, lower alkoxy, lower alkanol, halogen, or a compound represented by the formula (i)
- R 3 represents hydrogen, lower alkanol, halogen, hydroxy or lower alkoxy
- W 1 and W 2 are hydrogen and the other is hydrogen, hydroxy, lower alkylthio, or both are one
- a 1 and A 2 may be the same and hydrogen, or both may be represented by the formula (ii)
- R 6 is hydrogen, benzyloxycarbonyl, lower alkyl or lower alkanoyl.
- R 4 is hydrogen, lower alkyl, methoxymethyl or lower alkanol
- R 5 is hydrogen or lower alkoxycarbonyl.
- a pharmacologically acceptable salt thereof as an active ingredient can be provided as a therapeutic agent for thrombocytopenia.
- the therapeutic agent of the present invention is effective in increasing platelet count.
- Lower alkyl in the definition of each group of compound I means straight-chain or branched having 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopen Chill, hexyl and the like.
- alkyl part of lower alkoxy, lower alkoxycarbonyl and lower alkylthio is the same as the definition of lower alkyl described above.
- the lower alkanoyl includes formyl, acetyl, propionyl, isopropionyl, butyryl, valeryl, bivaloyl, hexanoyl, heptanyl and the like having 1 to 7 carbon atoms.
- Pharmaceutically acceptable salts of Compound I include inorganic salts such as hydrochloride, sulfate, phosphate, acetate, maleate, fumarate, tartrate, quaterate, lactate, and the like.
- Organic salts such as aspartate and glutamate are exemplified.
- Table 1 shows specific examples of compound I.
- n-Pr represents-(CH 2 ) 2 CH 3
- i-Pr represents -CH (CH 3 ) 2
- ⁇ - ⁇ represents-(CH 2 ) 3 CH 3
- n-Hex represents-(CH 2 ) 5 CH 3
- Bn represents benzyl.
- R 1A is hexyl and R 2A , R 3A and R 6A are hydrogen,
- R 1A is benzyl and R 2A , R 3A and R 6A are hydrogen;
- R 1 A is methyl, R 2A and R 3A are hydrogen, or R 6A is lower ⁇ alkyl
- R 1 A is hydrogen or lower alkyl
- R 6A is hydrogen
- R 2A and R 3A are lower alkyl
- R 1A , R 3A and R 6A are hydrogen and R 2A is lower alkoxy or
- R 1A is lower alkyl
- R 6A is hydrogen
- R 2A is hydroxy
- R 3A is hydroxy or hydrogen.
- Specific examples of the compound represented by the general formula ( ⁇ ) include the following: Compound I-20, I-21, 1-24, I29, 1-30, 1-31, I32 , I-33, I-39, I-47, 1-48, 1-49, I-50 and I-51.
- R la represents hexyl or benzyl
- Y represents benzyl or tert-butyl
- X represents I, Br or C 1
- R 2 and R 3 are as defined above. is there
- the compound (A) is reacted with R la X in a suitable solvent such as dimethylformamide (DMF) in the presence of a base such as sodium hydride to obtain a compound (EG).
- a suitable solvent such as dimethylformamide (DMF)
- a base such as sodium hydride
- R la X is a compound ( The reaction is completed in 1 to 8 hours at 23 to 30 ° C.
- the compound (EG) in which Y is benzyl is deprotected in a suitable solvent such as DMF in the presence of a catalyst such as 10% Pd / C or 10% Pd (0H) 2 / C in a stream of hydrogen.
- a catalyst such as 10% Pd / C or 10% Pd (0H) 2 / C in a stream of hydrogen.
- the compound (la) can be obtained by performing The catalyst is used in an amount of 0.1 to 2 times the weight of the compound (EG), and the reaction is completed at 0 to 80 ° C in 1 to 8 hours.
- R 6a represents a lower alkyl hydrogen or C 1 ⁇ C 5, RR 2.
- R 3, not a and W 2 are as defined above.
- Compound (Ib) can be obtained by reacting compound (N) with R 6a CHO in a suitable solvent such as tetrahydrofuran (THF) in the presence of a reducing agent such as sodium cyanoborohydride. 1 to 2 equivalents of the reducing agent and 1 to 5 equivalents of R 6a CHO are used based on the compound (N), and the reaction is completed at 0 to 30 ° C for 1 to 5 hours.
- a suitable solvent such as tetrahydrofuran (THF)
- a reducing agent such as sodium cyanoborohydride
- Compound (Ic) can be obtained by reacting compound ( ⁇ ) with a halogen or compound (P) in a suitable solvent such as chloroform and the like ( halogen or compound (P) is a compound (0) ) Is used in 0.8 to 1.5 equivalents, and the reaction is completed in 1 to 8 hours.
- R 2 is Arukanoiru of R 3 is 2 hydrogen or carbon number 7 Arukanoiru of 2 7 carbon atoms Compound (I d)
- Compound (R) and compound (Id) can be obtained by reacting compound (Q) with alkynyl chloride in the presence of a suitable Lewis acid such as aluminum chloride in a suitable solvent such as dichloromethane.
- a suitable Lewis acid such as aluminum chloride
- a suitable solvent such as dichloromethane.
- the alkanol chloride and Lewis acid are used in 1 to 8 equivalents to the compound (Q), and the reaction is completed at -10 to 30 ° C in 1 to 8 hours.
- Compound (Id) can also be obtained by catalytic reduction of compound (R) in the same manner as in the case of compound (Ia).
- R 3e is hydrogen or formyl
- RW 1 and W 2 are as defined above.
- Compound (Ie) can be obtained by reacting compound (Q) with dichloromethyl methyl ether in an appropriate solvent such as dichloromethane in the presence of a Lewis acid such as titanium tetrachloride. Titanium tetrachloride and Lewis acid are used in 1.5 to 3 equivalents based on compound (Q). The reaction is performed at 10-30 ° C for 1-5 hours. Ends with
- R 2e represents lower alkyl, and X has the same meaning as described above.
- Compound (R-2) can be obtained by reacting compound (R-1) with acetic anhydride or the like in an appropriate solvent such as THF in the presence of a base such as 4-dimethylaminopyridine. 1 to 8 equivalents of 4-dimethylaminopyridine and 5 to 20 equivalents of acetic anhydride are used for the compound (R-1), and the reaction is completed at 20 to 90 ° C in 5 to 15 hours.
- Compound (S) can be obtained by using compound (R-2) in an appropriate solvent such as chloroform in the presence of a base such as sodium bicarbonate and using an oxidizing agent such as metachloroperbenzoic acid.
- a base such as sodium bicarbonate
- an oxidizing agent such as metachloroperbenzoic acid.
- Sodium bicarbonate and metaclo-perbenzoic acid are used in 3 to 8 equivalents relative to compound (R-2), and the reaction is completed at 0 to 50 ° C in 5 hours to 1 day.
- Compound (T) is obtained by treating compound (S) with sodium methylate or the like in a suitable solvent such as dichloromethane. The reaction is completed in 5 to 30 minutes, using 1 to 5 equivalents of methyl methylate.
- Compound (Ig) can be obtained by reacting compound (V) with methoxymethyl chloride in an appropriate solvent such as THF in the presence of a base such as sodium hydride.
- a base such as sodium hydride.
- Sodium hydride and methoxymethyl chloride are used in 1 to 1.5 equivalents relative to compound (V), and the reaction is completed in 0 to 30 ° C for 1 to 2 days.
- R lb represents lower alkyl
- R 3b represents hydroxy or hydrogen
- R 7 represents OR 3a or hydrogen
- R 2b and R 3a are as defined above.
- Compound (X) can be obtained by subjecting compound (R-3) to the same operation as for compound (S).
- Compound (Z) can be obtained by performing compound (X) in the same manner as in the case of compound (T).
- Compound (Ih) can be obtained by performing compound (Z) in the same manner as compound (la).
- the isolation and purification of the product in the above production method can be carried out by appropriately combining methods used in ordinary organic synthesis, for example, extraction, crystallization, various types of chromatography and the like.
- Test Example 1 Megakaryocyte colony formation promoting action
- Bone marrow cells were obtained from cut sections of femur and tibia using an injector containing IMDM (430-2200EA manufactured by Gibco) solution, and the bone marrow cells were blown out into test tubes. After standing for 5 minutes, the supernatant was obtained using a pipette.
- IMDM 430-2200EA manufactured by Gibco
- Bone marrow cells (50000 cells), bovine serum albumin (2%: Sigma A4508), transfrin (600 ⁇ g / ml: Behringa-Mannheim 652202), IL-3 (lOOU / ml), cholesterol (16 / g / ml: 036-0641, manufactured by Pico Co.) and agar (0.6%: 0142-02, manufactured by Difco) were added with test compounds at various concentrations to obtain a mixture of the following components. hide put di Mesh one by 1 m 1, 3 7 ° C , 5% C0 2, 9 5% or more humidity conditions, and cultured for 7 days.
- the control was prepared by adding IL-3 alone to bone marrow cells, and the positive control was prepared by adding IL-6 to the above reaction composition to a concentration of 200 UZml. After completion of the culture, the agar was dried using filter paper (1001-055, manufactured by Pettmann), fixed with 2.5% glutaraldehyde, and then stained with acetylcholinesterase (ACHE staining).
- ACHE staining method A solution of 0.67 mg / ml of acetyl thiocholin iodide, 2.94 mg of sodium citrate, 7.5 mg / ml of copper (II) sulfate, and 1.65 mg / ml of potassium furocyanide In addition to the sample, it was left at room temperature for 4-6 hours.
- the number of colonies per dish was calculated using a microscope with four or more megakaryocyte cells stained reddish brown as one colony, and the results are shown in Table 2 as relative values to the control.
- Fee ⁇ ⁇ ⁇ ⁇ ⁇ fee 'Also, 111W phase 1 R Aj value lie. " ⁇ Article number concentrated UPC concentration- (, nM) no relative value
- Balb / c mice male, 7 weeks old were divided into two groups, one of which received only a solvent (1% lactic acid, 4% glucose aqueous solution) as a control group.
- a solvent 1% lactic acid, 4% glucose aqueous solution
- Compound I-11 was dissolved in the above solvent, and 0.2 ml was administered through the tail vein of the mouse once daily at a dose of 7.5 mg / kg for 5 days.
- the pharmaceutical composition of the present invention can be produced by uniformly mixing an effective amount of Compound I or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier as an active ingredient.
- the carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in a unit dosage form suitable for oral or parenteral administration such as ointment or injection.
- excipients such as lactose, glucose, sucrose, mannite, methylcellulose, etc .
- disintegrants such as starch, sodium alginate, calcium carboxymethylcellulose, crystalline cellulose, etc., eg, magnesium stearate, talc Lubricants such as gelatin, polyvinyl alcohol, polyvinylpyrrolidone, hydroxypropylcellulose, methylcellulose, etc., and surfactants such as sucrose fatty acid ester, sorbite fatty acid ester, etc.
- Tablets containing 50 to 20 mg of active ingredient per tablet are preferred.
- excipients such as lactose and sucrose
- disintegrating agents such as starch
- binders such as gelatin
- excipients such as lactose and mannite are used in accordance with standard procedures. Can be used.
- capsules gelatin, water, sucrose, acacia, sorbite, glycerin, crystalline cellulose, magnesium stearate, talc, and the like may be used in a conventional manner.
- Capsules containing 50 to 20 mg of the active ingredient per capsule are suitable.
- saccharides such as sucrose, water, ethanol and the like may be used in a conventional manner.
- ointment bases such as cellulose, liquid paraffin, and lanolin macrogol
- emulsifiers such as sodium lauryl lactate, benzalkonium chloride, sorbitan monofatty acid ester, carboxymethyl cellulose, sodium carb, arabia gum, etc. May be used in a conventional manner.
- injections for example, water, physiological saline, vegetable oils (eg, olive oil, peanut oil, etc.), solvents such as ethyl oleate and propylene glycol, and solubilizers such as sodium benzoate, sodium salicylate, and urethane Isotonic agents, for example, salt, glucose, etc., for example phenol, cresol, p-hydroxybenzoate, chlorobutano
- vegetable oils eg, olive oil, peanut oil, etc.
- solvents such as ethyl oleate and propylene glycol
- solubilizers such as sodium benzoate, sodium salicylate, and urethane Isotonic agents, for example, salt, glucose, etc., for example phenol, cresol, p-hydroxybenzoate, chlorobutano
- Preservatives such as glycerol, antioxidants such as ascorbic acid and sodium pyrosulfite may be used in a conventional manner.
- Compound I or a pharmacologically acceptable salt thereof can be administered orally or ointment or parenterally as an injection.
- the effective dose and frequency of administration vary depending on the dosage form, patient age, body weight, symptoms, etc. , Usually per day.
- Tablets were prepared by a conventional method from 1-1, 180 mg, lactose 90 mg, corn starch 40 mg, polyvinyl alcohol 4 mg, Avicel 28 mg and magnesium stearate lmg.
- Tablets were prepared by a conventional method from 122 mg and 180 mg of lactose, 90 mg of lactose, 40 mg of corn starch, 4 mg of polyvinyl alcohol, 28 mg of Avicel and lmg of magnesium stearate.
- Tablets were prepared by a conventional method from 1-48, 180 mg, lactose 90 mg, corn starch 40 mg, polyvinyl alcohol 4 mg, Avicel 28 mg and magnesium stearate lmg.
- I-I20 15 mg (36 mg) was obtained from Compound (E) 50 mg and 10% Pd / C 50 mg.
- the residue was dissolved in 20 ml of dichloromethane, cooled to 0 ° C., and 237 l (0.97 mmol) of a 28% sodium methanol solution was added, followed by stirring for 10 minutes. After completion of the reaction, the mixture was neutralized by adding 2N hydrochloric acid, extracted with black hole form, washed with water, and dried over sodium sulfate. After evaporating the solvent, the residue was purified by silica gel column chromatography (5% methanol / chloroform) to obtain 112.6fflg of the compound (Z-1) (54% yield).
- the present invention provides a therapeutic agent for thrombocytopenia useful as a pharmaceutical o
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69331228A DE69331228D1 (en) | 1992-09-21 | 1993-09-20 | Heilmittel für thrombozytopenia |
DE69331228T DE69331228T4 (de) | 1992-09-21 | 1993-09-20 | Heilmittel für thrombozytopenia |
US08/244,111 US5674867A (en) | 1992-09-21 | 1993-09-20 | Indolocarbazole derivatives and therapeutic method for stimulating megakaicyocyte production |
EP93919687A EP0630898B1 (en) | 1992-09-21 | 1993-09-20 | Thrombocytopenia remedy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25094192 | 1992-09-21 | ||
JP4/250941 | 1992-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994006799A1 true WO1994006799A1 (fr) | 1994-03-31 |
Family
ID=17215289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/001346 WO1994006799A1 (fr) | 1992-09-21 | 1993-09-20 | Remede contre la thrombopenie |
Country Status (6)
Country | Link |
---|---|
US (1) | US5674867A (ja) |
EP (1) | EP0630898B1 (ja) |
CA (1) | CA2123895A1 (ja) |
DE (2) | DE69331228D1 (ja) |
ES (1) | ES2171416T3 (ja) |
WO (1) | WO1994006799A1 (ja) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995032974A1 (en) * | 1994-06-01 | 1995-12-07 | Ciba-Geigy Ag | Carbazole derivatives as agents against multi-drug resistance |
WO1995032976A1 (en) * | 1994-06-01 | 1995-12-07 | Ciba-Geigy Ag | Polycyclic lactam derivatives for sensitizing multidrug-resistant cells to antitumour agents |
WO1995032975A1 (en) * | 1994-06-01 | 1995-12-07 | Ciba-Geigy Ag | Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents |
US5650407A (en) * | 1995-04-05 | 1997-07-22 | Cephalon, Inc. | Selected soluble esters of hydroxyl-containing indolocarbazoles |
US5686444A (en) * | 1995-04-05 | 1997-11-11 | Cephalon, Inc. | Selected soluble esters of hydroxyl-containing indolocarbazoles |
WO2001004125A1 (fr) * | 1999-07-13 | 2001-01-18 | Kyowa Hakko Kogyo Co., Ltd. | Derives de staurosporine |
WO2009080694A1 (en) | 2007-12-20 | 2009-07-02 | Novartis Ag | Thiazole derivatives used as pi 3 kinase inhibitors |
EP2261223A1 (en) | 2006-01-20 | 2010-12-15 | Novartis AG | Pyrimidine derivatives used as pi-3 kinase inhibitors |
WO2011000905A1 (en) | 2009-07-02 | 2011-01-06 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
EP2277595A2 (en) | 2004-06-24 | 2011-01-26 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
US7932262B2 (en) | 2006-04-06 | 2011-04-26 | Novartis Ag | Quinazolines for PDK1 inhibition |
WO2012016970A1 (en) | 2010-08-02 | 2012-02-09 | Novartis Ag | A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor |
WO2012104776A1 (en) | 2011-01-31 | 2012-08-09 | Novartis Ag | Novel heterocyclic derivatives |
WO2013061305A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
WO2013173283A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
WO2017077445A1 (en) | 2015-11-02 | 2017-05-11 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
EP4000619A1 (en) | 2013-12-06 | 2022-05-25 | Novartis AG | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0675125A1 (en) * | 1994-03-18 | 1995-10-04 | Kyowa Hakko Kogyo Co., Ltd. | A therapeutic agent for thrombocytopenia and indolocarbazole derivatives |
US5604219A (en) * | 1994-03-18 | 1997-02-18 | Kyowa Hakko Kogyo Co., Ltd. | Indolocarbazole derivatives that stimulate platelet production |
US6875865B1 (en) | 1996-06-03 | 2005-04-05 | Cephalon, Inc. | Selected derivatives of K-252a |
UA67725C2 (en) | 1996-06-03 | 2004-07-15 | Cephalon Inc | K-252a derivatives and a method for improvement of functioning and cell survival enhancement |
US6127401A (en) * | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
US6610727B2 (en) | 2000-10-06 | 2003-08-26 | Bristol-Myers Squibb Company | Anhydro sugar derivatives of indolocarbazoles |
US6653290B2 (en) | 2000-10-06 | 2003-11-25 | Bristol-Myers Squibb Company | Tumor proliferation inhibitors |
US6677450B2 (en) * | 2000-10-06 | 2004-01-13 | Bristol-Myers Squibb Company | Topoisomerase inhibitors |
WO2002077255A1 (en) * | 2001-03-22 | 2002-10-03 | Bristol-Myers Squibb Company | Topoisomerase i selective cytotoxic sugar derivatives of indolopyrrolocarbazoles |
TWI538914B (zh) * | 2014-10-03 | 2016-06-21 | 國立交通大學 | 蛋白質激酶之選擇性抑制劑、其醫藥組成物及其用途 |
WO2022006220A1 (en) * | 2020-07-02 | 2022-01-06 | Baylor University | Indolocarbazole analogs of staurosporine and methods of synthesis thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62120388A (ja) * | 1985-11-19 | 1987-06-01 | Meiji Seika Kaisha Ltd | Sf−2370物質ハロゲン化誘導体とその製造法 |
JPH0372485A (ja) * | 1989-05-23 | 1991-03-27 | Asahi Chem Ind Co Ltd | スタウロスポリンの誘導体 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5373501A (en) * | 1976-12-11 | 1978-06-30 | Kitasato Inst | Novel antibiotics amm2282 and process for preparing same |
JPS6041489A (ja) * | 1983-08-12 | 1985-03-05 | Kyowa Hakko Kogyo Co Ltd | 新規生理活性物質k―252 |
JPS62155284A (ja) * | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | 生理活性物質k−252の誘導体 |
JPS62220196A (ja) * | 1986-03-20 | 1987-09-28 | Kyowa Hakko Kogyo Co Ltd | 新規物質ucn―01 |
JPH0826037B2 (ja) * | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質k−252の誘導体 |
JPH0826036B2 (ja) * | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質k−252の誘導体 |
WO1988007045A1 (en) * | 1987-03-09 | 1988-09-22 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
IL86632A0 (en) * | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
JPS6420388A (en) * | 1987-07-14 | 1989-01-24 | Nakatsuka Kogyo | Method for expressing grain pattern on fabric |
JPH07113027B2 (ja) * | 1987-12-24 | 1995-12-06 | 協和醗酵工業株式会社 | K−252誘導体 |
JP2766360B2 (ja) * | 1988-02-04 | 1998-06-18 | 協和醗酵工業株式会社 | スタウロスポリン誘導体 |
JPH03220194A (ja) * | 1989-11-30 | 1991-09-27 | Asahi Chem Ind Co Ltd | スタウロスポリンカルボン酸誘導体 |
JPH04145085A (ja) * | 1990-09-25 | 1992-05-19 | Asahi Chem Ind Co Ltd | スタウロスポリンのγ―ラクタム環誘導体とそのアンモニウム塩 |
EP0540185A1 (en) * | 1991-10-10 | 1993-05-05 | Schering Corporation | 4'-(N-substituted-N-oxide)staurosporine derivatives |
DE69326388T2 (de) * | 1992-06-22 | 1999-12-30 | Kyowa Hakko Kogyo Kk | Verfahren zur Herstellung von Staurosporin-Derivaten |
-
1993
- 1993-09-20 DE DE69331228A patent/DE69331228D1/de not_active Expired - Fee Related
- 1993-09-20 ES ES93919687T patent/ES2171416T3/es not_active Expired - Lifetime
- 1993-09-20 EP EP93919687A patent/EP0630898B1/en not_active Expired - Lifetime
- 1993-09-20 CA CA002123895A patent/CA2123895A1/en not_active Abandoned
- 1993-09-20 WO PCT/JP1993/001346 patent/WO1994006799A1/ja active IP Right Grant
- 1993-09-20 DE DE69331228T patent/DE69331228T4/de not_active Expired - Lifetime
- 1993-09-20 US US08/244,111 patent/US5674867A/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62120388A (ja) * | 1985-11-19 | 1987-06-01 | Meiji Seika Kaisha Ltd | Sf−2370物質ハロゲン化誘導体とその製造法 |
JPH0372485A (ja) * | 1989-05-23 | 1991-03-27 | Asahi Chem Ind Co Ltd | スタウロスポリンの誘導体 |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995032974A1 (en) * | 1994-06-01 | 1995-12-07 | Ciba-Geigy Ag | Carbazole derivatives as agents against multi-drug resistance |
WO1995032976A1 (en) * | 1994-06-01 | 1995-12-07 | Ciba-Geigy Ag | Polycyclic lactam derivatives for sensitizing multidrug-resistant cells to antitumour agents |
WO1995032975A1 (en) * | 1994-06-01 | 1995-12-07 | Ciba-Geigy Ag | Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents |
US5650407A (en) * | 1995-04-05 | 1997-07-22 | Cephalon, Inc. | Selected soluble esters of hydroxyl-containing indolocarbazoles |
US5686444A (en) * | 1995-04-05 | 1997-11-11 | Cephalon, Inc. | Selected soluble esters of hydroxyl-containing indolocarbazoles |
USRE38332E1 (en) | 1995-04-05 | 2003-11-25 | Cephalon, Inc. | Selected soluble esters of hydroxyl-containing indolocarbazoles |
WO2001004125A1 (fr) * | 1999-07-13 | 2001-01-18 | Kyowa Hakko Kogyo Co., Ltd. | Derives de staurosporine |
EP2277595A2 (en) | 2004-06-24 | 2011-01-26 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
EP2261223A1 (en) | 2006-01-20 | 2010-12-15 | Novartis AG | Pyrimidine derivatives used as pi-3 kinase inhibitors |
US7932262B2 (en) | 2006-04-06 | 2011-04-26 | Novartis Ag | Quinazolines for PDK1 inhibition |
WO2009080694A1 (en) | 2007-12-20 | 2009-07-02 | Novartis Ag | Thiazole derivatives used as pi 3 kinase inhibitors |
WO2011000905A1 (en) | 2009-07-02 | 2011-01-06 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
WO2012016970A1 (en) | 2010-08-02 | 2012-02-09 | Novartis Ag | A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor |
WO2012104776A1 (en) | 2011-01-31 | 2012-08-09 | Novartis Ag | Novel heterocyclic derivatives |
WO2013061305A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
WO2013173283A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
EP4000619A1 (en) | 2013-12-06 | 2022-05-25 | Novartis AG | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
WO2017077445A1 (en) | 2015-11-02 | 2017-05-11 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
Also Published As
Publication number | Publication date |
---|---|
EP0630898B1 (en) | 2001-11-28 |
DE69331228D1 (en) | 2002-01-10 |
US5674867A (en) | 1997-10-07 |
ES2171416T3 (es) | 2002-09-16 |
DE69331228T2 (de) | 2002-05-23 |
EP0630898A4 (en) | 1995-04-26 |
DE69331228T4 (de) | 2002-09-05 |
EP0630898A1 (en) | 1994-12-28 |
CA2123895A1 (en) | 1994-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994006799A1 (fr) | Remede contre la thrombopenie | |
JP3411280B2 (ja) | 血小板減少症治療剤 | |
JP2510335B2 (ja) | Dc―88a誘導体 | |
US6262083B1 (en) | Genipin derivative having liver protection activity | |
WO2018019297A1 (zh) | 异喹啉酮类化合物及其制备抗病毒药物的应用 | |
WO2020001420A1 (zh) | 一类细胞坏死抑制剂及其制备方法和用途 | |
SK26094A3 (en) | O-heteroaryl-, o-alkylheteroaryl-, o-alkenylheteroaryl- and o-alkylheteroaryl macrolides compounds, the method of their production and pharmaceutical preparations containing those | |
WO2017028798A1 (zh) | 哒嗪酮类化合物、其制备方法、药物组合物及用途 | |
WO2016192132A1 (zh) | 作为alk抑制剂的嘧啶衍生物 | |
EA009729B1 (ru) | 13-членные азалиды и их применение в качестве антибиотических агентов | |
CN111960998A (zh) | 硝羟喹啉衍生物及其制备方法和用途 | |
JPH10503525A (ja) | カンプトテシン誘導体及びその製造方法 | |
JPH11513040A (ja) | モルホリニルアントラサイクリン誘導体 | |
CN112574269A (zh) | 嘌呤核苷类化合物及其用途 | |
US6514944B2 (en) | Macrolide antiinfective agents | |
CA2062932A1 (en) | 9-deoxo-9(z)-hydroxyiminoerythromycin a and o-derivatives thereof | |
US20020156028A1 (en) | Macrolide antiinfective agents | |
JPH10502058A (ja) | アリール、アルキル、アルケニルおよびアルキニルマクロライド | |
JP3497168B2 (ja) | 抗腫瘍活性を有する2−アミノアルキル−5−アミノアルキルアミノ置換イソキノインダゾール−6−(2h)−オン類 | |
WO2022161479A1 (zh) | 适用于抗体-药物偶联物的毒素分子 | |
WO2021031960A1 (zh) | 一类2-氨基嘧啶类化合物及其药物组合物和用途 | |
JP4038245B2 (ja) | 新規なフェナンスリジニウム誘導体 | |
SE500732C2 (sv) | Nya antracyklinglykosidderivat, förfarande för framställning därav samt farmaceutiska kompositioner därav | |
US6869971B1 (en) | UCS1025 derivatives | |
EP0449294A1 (en) | Hydroxymethyl-indolizidines and quinolizidines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2123895 Country of ref document: CA Ref document number: 1993919687 Country of ref document: EP Ref document number: 08244111 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1993919687 Country of ref document: EP |
|
CFP | Corrected version of a pamphlet front page |
Free format text: UNDER INID NUMBER(43)"INTERNATIONAL PUBLICATION DATE",REPLACE THE EXISTING TEXT BY "940331" |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993919687 Country of ref document: EP |